参考文献/References:
[1] Wilson WA,Gharavi AE,Koike T,et al.International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop[J].Arthritis Rheum,1999,42(7):1309-1311.
[2] Miyakis S,Lockshin MD,Atsumi T,et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome(APS)[J].J Thromb Haemost,2006,4(2):295-306.
[3] Asherson RA.New subsets of the antiphospholipid syndrome in 2006: "PRE-APS"(probable APS)and microangiopathic antiphospholipid syndromes("MAPS")[J].Autoimmun Rev,2006,6(2):76-80.
[4] Lim W.Antiphospholipid antibody syndrome[J].Hematology Am Soc Hematol Educ Program,2009,51(5):233-239.
[5] Rodrigues CE,Carvalho JF,Shoenfeld Y.Neurological manifestations of antiphospholipid syndrome[J].Eur J Clin Invest,2010,40(4):350-359.
[6] Chighizola CB,Andreoli L,De Jesus GR,et al.The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature[J].Lupus,2015,24(9):980-984.
[7] Galli M,Luciani D,Bertolini G,et al.Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature[J].Blood,2003,101(5):1827-1832.
[8] Brey RL,Muscal E,Chapman J.Antiphospholipid antibodies and the brain: a consensus report[J].Lupus,2011,20(2):153-157.
[9] Gris JC,Nobile B,Bouvier S.Neuropsychiatric presentations of antiphospholipid antibodies[J].Thromb Res,2015,135(Suppl 1):S56-S59.
[10] Tanne D,Katzav A,Beilin O,et al.Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome[J].Neurobiol Dis,2008,30(1):56-64.
[11] Ziporen L,Polak-Charcon S,Korczyn DA,et al.Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model[J].Clin Dev Immunol,2004,11(1):67-75.
[12] Chapman J,Cohen-Armon M,Shoenfeld Y,et al.Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes[J].Lupus,1999,8(2):127-133.
[13] Katzav A,Pick CG,Korczyn AD,et al.Hyperactivity in a mouse model of the antiphospholipid syndrome[J].Lupus,2001,10(7):496-499.
[14] Ruiz-Irastorza G,Cuadrado MJ,Ruiz-Arruza I,et al.Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies[J].Lupus,2011,20(2):206-218.
[15] Danowski A,Rego J,Kakehasi AM,et al.Guidelines for the treatment of antiphospholipid syndrome[J].Rev Bras Reumatol,2013,53(2):184-192.